

FORM 9

NOTICE OF PROPOSED ISSUANCE OF LISTED SECURITIES¹⁾ **(or securities convertible or exchangeable into listed securities)**

Please complete the following:

Name of Listed Issuer: Veritas Pharma Inc. (the "Issuer").

Trading Symbol: VRT.

Date: February 6, 2017.

Is this an updating or amending Notice: ☒ Yes ☐ No

If yes provide date(s) of prior Notices: January 20, 2017.

Issued and Outstanding Securities of Issuer Prior to Issuance: 36,291,090.

Date of News Release Announcing Private Placement: January 10, 2017

Closing Market Price on Day Preceding the Issuance of the News Release: \$0.36

1. Private Placement (if shares are being issued in connection with an acquisition (either as consideration or to raise funds for a cash acquisition), proceed to Part 2 of this form)

Full Name & Residential Address of Placee	Number of Securities Purchased or to be Purchased	Purchase price per Security (CDN\$)	Conversion Price (if Applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed	Payment Date(1)	Describe relationship to Issuer (2)
Marapharm Ventures Inc, Box 20059 TCM, Kelowna, BC V1Y 9H2	5,000,000 warrants	\$0.05	\$0.40 per warrant	s. 2.5(1) of NI 45-106	5,000,000	January 4, 2017	I
David Greenway, 2507 - 583 Beach Crescent, Vancouver, BC V6Z 3E4	1,500,000 warrants	\$0.05	\$0.40 per warrant	s. 2.3(1) of NI 45-106	1,000,000	January 4, 2017	N/A
Bernard Block Inc., 200-537 Leon Ave., Kelowna, BC V1Y 9Z9	3,500,000 warrants	\$0.05	\$0.40 per warrant	s. 2.3(1) of NI 45-106	0	January 4, 2017	N/A

(1) Indicate date each placee advanced or is expected to advance payment for securities. Provide details of expected payment date, conditions to release of funds etc. Indicate if the placement funds been placed in trust pending receipt of all necessary approvals.

(2) Indicate if Related Person.

¹An issuance of non-convertible debt does not have to be reported unless it is a significant transaction as defined in Policy 7, in which case it is to be reported on Form 10.

1. Total amount of funds to be raised: \$500,000
2. Provide full details of the use of the proceeds. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material. The proceeds will be used for working capital purposes.
3. Provide particulars of any proceeds which are to be paid to Related Persons of the Issuer: N/A
4. If securities are issued in forgiveness of indebtedness, provide details and attach the debt agreement(s) or other documentation evidencing the debt and the agreement to exchange the debt for securities.
5. Description of securities to be issued:
 - (a) Class common share purchase warrants ("Warrants")
 - (b) Number 10,000,000 Warrants
 - (c) Price per security \$0.05 per Warrant
 - (d) Voting rights No voting rights are attached to the Warrants
6. Provide the following information if Warrants, (options) or other convertible securities are to be issued:
 - (a) Number 10,000,000 Warrants
 - (b) Number of securities eligible to be purchased on exercise of Warrants (or options) 10,000,000 common shares
 - (c) Exercise price \$0.40 per Warrant.
 - (d) Expiry date 12 months from the date of issuance. In the event that the closing sales price of the Issuers common shares (or the closing bid, if no sales were reported on a trading day) as quoted on the Canadian Securities Exchange (or such other securities exchange, quotation system or market on which such common shares are listed and where a majority of the trading volume of such common shares

occurs) exceeds \$0.80 for a period of ten (10) consecutive trading days, the Corporation may, within five days of such event, provide notice by way of press release to the Subscriber of early expiry, and thereafter the Warrants shall expire on that date which is thirty (30) days from the date such notice is given. The Warrants will be governed by the terms and conditions set out in the certificate representing the Warrants (the "Warrant Certificates") delivered to the Subscriber at the Closing. (the "Accerlation")

7. Provide the following information if debt securities are to be issued: N/A
- (a) Aggregate principal amount _____ .
- (b) Maturity date _____ .
- (c) Interest rate _____ .
- (d) Conversion terms _____ .
- (e) Default provisions _____ .
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the placement (including warrants, options, etc.):
- (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the placement (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): 1015991 BC Ltd., 700 Hendry Ave, North Vancouver BC V7L 0B6. .
- (b) Cash \$50,000 which represents 10% of the proceeds raised by such finder. _____ .
- (c) Securities N/A _____ .
- (d) Other N/A _____ .
- (e) Expiry date of any options, warrants etc. N/A _____ .
- (f) Exercise price of any options, warrants etc. N/A _____ .
9. State whether the sales agent, broker, dealer or other person receiving compensation in connection with the placement is Related Person or has any other relationship with the Issuer and provide details of the relationship N/A _____ .
10. Describe any unusual particulars of the transaction (i.e. tax "flow through" shares, etc.).

N/A

11. State whether the private placement will result in a change of control.

Marapharm Ventures Inc. ("Marapharm") of Box 20059 TCM, Kelowna, BC V1Y 9H2 currently holds 13.78% on an undiluted basis and will hold 21.60% on an diluted basis of the Issuer.

12. Where there is a change in the control of the Issuer resulting from the issuance of the private placement shares, indicate the names of the new controlling shareholders. Marapharm is a public company listed on the CSE trading under symbol MDM.

13. Each purchaser has been advised of the applicable securities legislation restricted or seasoning period. All certificates for securities issued which are subject to a hold period bear the appropriate legend restricting their transfer until the expiry of the applicable hold period required by National Instrument 45-102..

2. Acquisition N/A

1. Provide details of the assets to be acquired by the Issuer (including the location of the assets, if applicable). The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the transaction without reference to any other material: _____

2. Provide details of the acquisition including the date, parties to and type of agreement (eg: sale, option, license etc.) and relationship to the Issuer. The disclosure should be sufficiently complete to enable a reader to appreciate the significance of the acquisition without reference to any other material: _____

3. Provide the following information in relation to the total consideration for the acquisition (including details of all cash, securities or other consideration) and any required work commitments:

(a) Total aggregate consideration in Canadian dollars: _____

(b) Cash: _____

(c) Securities (including options, warrants etc.) and dollar value: _____

(d) Other: _____

(e) Expiry date of options, warrants, etc. if any: _____

(f) Exercise price of options, warrants, etc. if any: _____

(g) Work commitments: _____

4. State how the purchase or sale price was determined (e.g. arm's-length negotiation, independent committee of the Board, third party valuation etc).
5. Provide details of any appraisal or valuation of the subject of the acquisition known to management of the Issuer: _____.
6. The names of parties receiving securities of the Issuer pursuant to the acquisition and the number of securities to be issued are described as follows:

Name of Party (If not an individual, name all insiders of the Party)	Number and Type of Securities to be Issued	Dollar value per Security (CDN\$)	Conversion price (if applicable)	Prospectus Exemption	No. of Securities, directly or indirectly, Owned, Controlled or Directed by Party	Describe relationship to Issuer ⁽¹⁾

(1) Indicate if Related Person

7. Details of the steps taken by the Issuer to ensure that the vendor has good title to the assets being acquired: _____.
8. Provide the following information for any agent's fee, commission, bonus or finder's fee, or other compensation paid or to be paid in connection with the acquisition (including warrants, options, etc.):
 - (a) Details of any dealer, agent, broker or other person receiving compensation in connection with the acquisition (name, address. If a corporation, identify persons owning or exercising voting control over 20% or more of the voting shares if known to the Issuer): _____.
 - (b) Cash _____.
 - (c) Securities _____.
 - (d) Other _____.
 - (e) Expiry date of any options, warrants etc. _____.
 - (f) Exercise price of any options, warrants etc. _____.
9. State whether the sales agent, broker or other person receiving compensation in connection with the acquisition is a Related Person or has any other relationship with

the Issuer and provide details of the relationship. _____

10. If applicable, indicate whether the acquisition is the acquisition of an interest in property contiguous to or otherwise related to any other asset acquired in the last 12 months. _____

_____.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance on behalf of the Issuer.
2. As of the date hereof there is not material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CSE Policy 1).
4. All of the information in this Form 9 Notice of Issuance of Securities is true.

Dated February 6, 2017

David Alexander
Name of Director or Senior Officer

"David Alexander"
Signature

CFO
Official Capacity